ABLATIVE AND PROPHYLACTIC EFFECTS OF BCG TOKYO 172 STRAIN FOR INTRAVESICAL TREATMENT IN PATIENTS WITH SUPERFICIAL BLADDER CANCER AND CARCINOMA IN SITU OF THE BLADDER

AbstractReliable factors predicting the disease course of non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) are unavailable. Molecular subtypes have potential for prognostic stratification of muscle-invasive bladder cancer, while their value for CIS patients is unknown. Here, the prognostic impact of both clinico-pathological parameters, including CIS focality, and immunohistochemistry-based surrogate subtypes was analyzed in a cohort of high-risk NMIBC patients with CIS. In 128 high-risk NMIBC patients with CIS, luminal (KRT20, GATA3, ERBB2) and basal (KRT5/6, KRT14) surrogate markers as well as p53 were analyzed in 213–231 biopsies. To study inter-lesional heterogeneity of CIS, marker expression in independent CIS biopsies from different bladder localizations was analyzed. Clinico-pathological parameters and surrogate subtypes were correlated with recurrence-free (RFS), progression-free (PFS), cancer-specific (CSS), and overall survival (OS). Forty-six and 30% of CIS patients exhibited a luminal-like (KRT20-positive, KRT5/6-negative) and a null phenotype (KRT20-negative, KRT5/6-negative), respectively. A basal-like subtype (KRT20-negative, KRT5/6-positive) was not observed. A significant degree of inter-lesional CIS heterogeneity was noted, reflected by 23% of patients showing a mixed subtype. Neither CIS surrogate subtype nor CIS focality was associated with patient outcome. Patient age and smoking status were the only potentially independent prognostic factors predicting RFS, PFS, OS, and PFS, respectively. In conclusion, further clarification of heterogeneity of surrogate subtypes in HR NMIBC and their prognostic value is of importance with regard to potential implementation of molecular subtyping into clinical routine. The potential prognostic usefulness of patient age and smoking status for high-risk NMIBC patients with CIS needs further validation.

Download Full-text

Intravescial chemotherapy of carcinoma in situ in bladder cancer

Urology ◽

10.1016/s0090-4295(84)80114-4 ◽

1984 ◽

Vol 23 (3) ◽

pp. 37-39 ◽

Cited By ~ 2

Author(s):

Folke Edsmyr ◽

Lennart Andersson ◽

Pier-Luigi Esposti

Keyword(s):

Bladder Cancer ◽

Carcinoma In Situ

Download Full-text

Intravesical Treatment of Superficial Bladder Cancer

Combination Therapy in Urological Malignancy - Clinical Practice in Urology ◽

10.1007/978-1-4471-1655-4_5 ◽

1989 ◽

pp. 83-93

Author(s):

W. W. Bonney

Keyword(s):

Bladder Cancer ◽

Superficial Bladder Cancer ◽

Intravesical Treatment

Download Full-text

How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices

Urologia Journal ◽

10.1177/0391560319899303 ◽

2020 ◽

Vol 87 (3) ◽

pp. 142-148

Author(s):

Petros Sountoulides ◽

Wilbert Fana Mutomba ◽

Emmanouil Bouras ◽

Jieqi Lim ◽

Andreas Bourdoumis ◽

...

Keyword(s):

Bladder Cancer ◽

Carcinoma In Situ ◽

Real Life ◽

Invasive Bladder Cancer ◽

Detrusor Muscle ◽

Bladder Tumors ◽

Recurrence Rates ◽

Muscle Invasive Bladder Cancer ◽

Muscle Invasive

Objective: The aim of this study was to assess the quality of TURBT (transurethral resection of bladder tumor) using surrogate parameters and evaluate adherence to the guidelines regarding the management of bladder tumors. Materials and methods: A clinical audit of all new diagnosis of bladder cancer was undertaken from January 2016 to January 2017. A total of 101 new bladder cancer cases were included. Surrogates of TURBT quality including presence of detrusor in the specimen, rate of re-TUR, presence of carcinoma in situ, and 3-month recurrence rates were analyzed. Adherence to guidelines regarding management of non-muscle invasive bladder cancer including time to re-TUR and utilization of single instillation chemotherapy was evaluated. Results: Absence of detrusor muscle in the specimen of the initial TURBT was noted in 22.8% of the cases. The chance of including muscle in the specimen was almost four-fold for tumors larger than 3 cm. A single instillation of intravesical chemotherapy following TURBT was administered in only 40% of eligible patients; 54.3% of patients had a re-TUR, the majority (61.3%) for high-grade non-muscle invasive bladder cancer on initial TURBT. Re-TUR was done on average 10 weeks after initial TURBT. The 3-month recurrence rate was 36.0% with larger tumors (>3 cm) being more prone to early recurrences. Early recurrences were not affected by intravesical instillations with bacillus Calmette–Guérin or mitomycin C although there was a positive association between the presence of carcinoma in situ on initial resection and early recurrences. Discussion and conclusion: One in two patients will have a re-TUR, and approximately one in two patients will have tumor on re-TUR. Single immediate chemotherapy instillations after TURBT are underutilized. The presence of carcinoma in situ on initial TURBT and tumor size were predictors of early recurrences.

Download Full-text